Value of Seattle’s top 10 biotechs has fallen
This is the second in a series of posts I plan on the changing state of the local biotech industry. Last week, I wrote about the contracting biotech job market here.
View ArticleNew pre-clinical data out at conference
Pre-clinical data galore is coming out of the Annual Meeting of the American Association of Cancer Research in San Diego today.
View ArticleNoted: Local firms present at ASCO
Several firms are presenting data today at the American Society of Clinical Oncology meeting in Chicago today.
View ArticleNoted: Oncothyreon appoints two to its board
Oncothyreon said it had appointed Daniel Spiegelman, the CFO at CV Therapeutics in Palo Alto, Calif., and Stephen Burley, the chief scientific officer of SGX Pharmaceuticals in San Diego, Calif., to...
View ArticleToday’s clinical trial news round-up
Oncothyreon said it had enrolled its first patient in a phase one trial of its PX-866 drug. PX-866 is Oncothyreon's fourth product candidate in clinical trials. The trial will enroll 63 patients with...
View ArticleNoted: Former Immunex CFO joins Omeros board
Seattle's Omeros Corp. said today it had appointed David Mann to its board. Mann was CFO at Seattle's Immunex from 1999 until it it was purchased by Amgen in 2002. He is also on the board of Seattle's...
View ArticleAnother Seattle biotech faces delisting
Oncothyreon said Wednesday it had received a notice from the Nasdaq Stock Market saying that it was not in compliance with a requirement that its market value be at least $50 million.
View Article
